Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 27931-27940 Newer>

The Motley Fool January 4, 2008 Timothy M. Otte	Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.
The Motley Fool January 4, 2008 Rich Smith	Quick Take: Ceradyne Delivers on a Promise Defense contractor and ceramics specialist Ceradyne lands a $400 million contract to supply "ESAPI" body armor to the U.S. Special Forces command.
The Motley Fool January 4, 2008 Mac Greer	Fool Video: The Right Stocks in the Right Places Buffalo Wild Wings or Chipotle? Amazon.com or Blue Nile? American Eagle Outfitters or Urban Outfitters? What are consumers buying and what should investors buy? These questions are discussed in this video.
The Motley Fool January 4, 2008 Tim Beyers	And the Best Stock for 2008 Is ... Apple is chosen in a survey of investors as the stock to have in 2008.
The Motley Fool January 4, 2008 Todd Wenning	Happy Hour at Sonic Sonic reported generally positive first-quarter results; the stock was up as much as 5% in after-hours trading.
The Motley Fool January 4, 2008 Chuck Saletta	Don't Forget the Only Reason to Invest There is exactly one reason to invest: To turn a little cash today into more cash tomorrow, or next year, or 10 to 20 years from now. You get the point.
The Motley Fool January 4, 2008 Selena Maranjian	Bad News in Housing If you're looking for bad news related to the housing market and its effect on the overall stock market, it's not hard to find.
The Motley Fool January 4, 2008 Rick Aristotle Munarriz	Good Riddance to Tax Refund Loans? The Internal Revenue Service is considering putting restrictions on this loan, a product that tax preparation specialists such as H&R Block and Jackson Hewitt have been promoting for years.
The Motley Fool January 4, 2008 Matt Koppenheffer	The Cost of Cash for Merrill Money isn't free for anybody -- least of all an investment bank that has written down billions of dollars in bad paper.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
<Older 27931-27940 Newer> Return to current articles.